![筑波大学T-CReDO](/img/default-banner.jpg)
- 44
- 5 614
筑波大学T-CReDO
Japan
Registrace 10. 04. 2020
*Research Studio: Connecting Researchers with Clinicians and Investors*
T-CReDO provides a medical entrepreneurship training program "Research Studio."
T-CReDO provides a medical entrepreneurship training program "Research Studio."
2024 SPARK Translational Research Bootcamp: Report #2(HaoLan Yang)
Related program of Research Studio powered by SPARK
zhlédnutí: 59
Video
2024 SPARK Translational Research Bootcamp: Report #3(Nadin Mohamed Ebrahim Elgzzar)
zhlédnutí 39Před 28 dny
2024 SPARK Translational Research Bootcamp: Report #3(Nadin Mohamed Ebrahim Elgzzar)
2024 SPARK Translational Research Bootcamp: Report #5 (Adeline Castro)
zhlédnutí 87Před 28 dny
Related program of Research studio powered by SPARK
2024 SPARK Translational Research Bootcamp: Report #4(Kim Taehyeong)
zhlédnutí 48Před 28 dny
Related program of Research Studio powered by SPARK
2024 SPARK Translational Research Bootcamp: Report #1(Zeynab Javanfekr Shahri)
zhlédnutí 65Před 28 dny
A related program of Research Studio powered by SPARK
ER Stress Research Institute (Research Studio 2023 Business Pitch)
zhlédnutí 125Před 4 měsíci
A medical entrepreneurship program "Research Studio" provides a pitch opportunity for the participants. ER Stress Research Institute has completed the training program in FY2023. Program details: resstplatform.org/research-studio/
Antibody Therapeutics, Inc【Business Pitch @Research Studio2023】
zhlédnutí 133Před 6 měsíci
A medical entrepreneurship program "Research Studio" provides a pitch opportunity for the participants. Antibody Therapeutics, Inc has completed the training program in FY2023. Program details: resstplatform.org/research-studio/
TOMOCLOUD【Business Pitch @Research Studio2023】
zhlédnutí 88Před 6 měsíci
A medical entrepreneurship program "Research Studio" provides a pitch opportunity for the participants. TOMOCLOUD has completed the training program in FY2023. Program details: resstplatform.org/research-studio/
SPINE CHRONICLE JAPAN【Business Pitch @Research Studio2023】
zhlédnutí 87Před 6 měsíci
A medical entrepreneurship program "Research Studio" provides a pitch opportunity for the participants. SPINE CHRONICLE JAPAN has completed the training program in FY2023. Program details: resstplatform.org/research-studio/
Physiaura 【Business Pitch @Research Studio2023】
zhlédnutí 36Před 6 měsíci
A medical entrepreneurship program "Research Studio" provides a pitch opportunity for the participants. Physiaura has completed the training program in FY2023. Program details: resstplatform.org/research-studio/
UBeing(Final Pitch@Research Studio 2022)
zhlédnutí 87Před rokem
A medical entrepreneurship program "Research Studio" provides a pitch opportunity for the participants. UBeing has completed the training program in FY2022. Program details: resstplatform.org/research-studio/
PRD Therapeutics(Final Pitch @Research Studio 2022)
zhlédnutí 128Před rokem
A medical entrepreneurship program "Research Studio" provides a pitch opportunity for the participants. PRD Therapeutics has completed the training program in FY2022. Program details: resstplatform.org/research-studio/
MediGear(Final Pitch@Research Studio 2022)
zhlédnutí 57Před rokem
A medical entrepreneurship program "Research Studio" provides a pitch opportunity for the participants. MediGear has completed the training program in FY2022. Program details: resstplatform.org/research-studio/
FerroptoCure(Final Pitch@Research Studio 2022)
zhlédnutí 86Před rokem
A medical entrepreneurship program "Research Studio" provides a pitch opportunity for the participants. FerroptoCure has completed the training program in FY2022. Program details: resstplatform.org/research-studio/
CLOVERNA(Final Pitch@Research Studio 2022)
zhlédnutí 109Před rokem
A medical entrepreneurship program "Research Studio" provides a pitch opportunity for the participants. CLOVERNA has completed the training program in FY2022. Program details: resstplatform.org/research-studio/
Restore Vison (Final Pitch@Research Studio 2021)
zhlédnutí 714Před 2 lety
Restore Vison (Final Pitch@Research Studio 2021)
Syrinx (Final Pitch@Research Studio 2021)
zhlédnutí 421Před 2 lety
Syrinx (Final Pitch@Research Studio 2021)
NGENIESS Biosciences (Final Pitch@Research Studio 2021)
zhlédnutí 70Před 2 lety
NGENIESS Biosciences (Final Pitch@Research Studio 2021)
Bio MIT (Final Pitch@Research Studio 2021)
zhlédnutí 41Před 2 lety
Bio MIT (Final Pitch@Research Studio 2021)
MediGear (Final Picth@Research Studio 2021)
zhlédnutí 75Před 2 lety
MediGear (Final Picth@Research Studio 2021)
atDose (Final Pitch@Research Studio 2021)
zhlédnutí 44Před 2 lety
atDose (Final Pitch@Research Studio 2021)
ALAN (Final Pitch@Research Studio 2021)
zhlédnutí 77Před 2 lety
ALAN (Final Pitch@Research Studio 2021)
Biomedical Innovation and Entrepreneurship (BIE) Training Course 2021: Report #2
zhlédnutí 44Před 3 lety
Biomedical Innovation and Entrepreneurship (BIE) Training Course 2021: Report #2
Biomedical Innovation and Entrepreneurship (BIE) Training Course 2021: Report #1
zhlédnutí 35Před 3 lety
Biomedical Innovation and Entrepreneurship (BIE) Training Course 2021: Report #1
Research Studio 2020 (UCSD training course): Neurit
zhlédnutí 115Před 3 lety
Research Studio 2020 (UCSD training course): Neurit
Research Studio 2020 (UCSD training course): VesicA Intelligence
zhlédnutí 56Před 3 lety
Research Studio 2020 (UCSD training course): VesicA Intelligence
Hi could you not input the data recieved from this device &convertbinto AI voice Gen real-time using internet
The following are questions from an IPF patient. What is the competitive advantage over oral antifibrotic agents like pirfenidone and nintedanib? Is the endpoint the rate of FVC reduction? Wouldn't a price equivalent to an oral antifibrotic be a viable business model for a biologic? What is the rationale for a possible value eflax point before showing Phase 2 results?
Whoops, sorry not for responding earlier. This monoclonal antibody (mAb) drug has several advantages over the standard care of drugs you mentioned. Mechanistically, target of this mAb is on fibroblasts and this mAb directly suppress fibroblasts, while targets of P&N are not on fibroblasts but on immune cells though both are explained to have the effects on the fibroblast, in their official attached documents. Therefore, both of the drugs may have unwanted effects on immune and other relevant cells. In contrast the mAb targets the matrix protein receptor, integrin α8β1, on fibroblasts and suppress fibroblast activation by two ways: blocking 1) matrix signals, 2) TGFβ activation. TGFβ is known as a Boss of fibroblast activation through its receptor expressed on fibroblasts. In the second question for the endpoint, we think the mAb do not only reduce the declining rate, but think stops or even revert FVC, but we still do not know until we inject to humans. At least in a mouse model, the mAb suppressed more of the fibrogeneis by bleomycine than Nintedanib. Finally, with respect to the price, generally newer drugs are a little bit more expensive. And you are right, manufacturing of biologics costs more than chemicals. The decision is made by the ministry in charge. Any way if it is too expensive, which is definitely not what we want.
When to use it in the clinic?
0:48 This private method earn 5000$ in 2 days codz2019.blogspot.com/2020/09/150-case-study.html
Great!!